GI Hepatobiliary

Hepatocellular Carcinoma

- Localized
  - IRB #2377
    - A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

- No Prior Therapy
  - 1st line
    - IRB 11974
      - SOLACE: A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization with Drug-Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally-Advanced Hepatocellular Carcinoma
  - Prior Therapy
    - 2nd line
      - IRB #15077
        - 9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
      - IRB #11746
        - I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
      - IRB #15816
        - A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)
      - No Trials Currently Available

Cholangiocarcinoma

- 1st or 2nd Line
  - No Trials Currently Available

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

11/15/2016

www.ohsu.edu/cancer